News | December 09, 2023
Zepbound is now available in US for adults living with obesity
Express Scripts to add Zepbound to National Preferred Formulary
Express Scripts to add Zepbound to National Preferred Formulary
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
